ASCO 2020 . . . First-line treatment of liver cancer! The results of the test of the innovative drug Donatini, which was independently developed in China, were encouraging, and the median total survival period (mOS) reached 12.1 months.

May 30, 2020, Suzhou Zeyin Biopharmaceutical Co., Ltd(referred to as: Zeye Pharmaceuticals) announced: Dafini first-line treatment of advanced hepatocellular carcinoma clinical research ZGDH3, at the 56th Annual American Cancer Conference (ASCO) by oral report to the world announced the latest research results, proving the breakthrough efficacy of Donovan liver cancer treatmentIn recent years, China has made fruitful achievements in promoting independent innovation drugsSince the launch and implementation of the "major new drug creation" science and technology major special project son in 2008, China's new drug research and development and the internationalization of the pharmaceutical industry has continued to advanceAs of July 2019, there were 44 class 1 new drugs supported by the "National Major New Drug Creation Special" aloneAmong them, The Phase III trial of Dafinni- ZGDH3 research is one of the major breakthroughs in the research and development process of "national major new drug creation special" drugsThis large-scale clinical study of innovative drugs, developed by China and led by Chinese scholars, has been highly recognized by academic circles at home and abroad, and is an important step in the field of liver cancer treatment in the world in the past decadeliver cancer is a common cancer in the world, especially in ChinaThe number of new cases of liver cancer worldwide each year is 841,000, and 784,000 deaths are reportedChina's annual number of new cases and deaths accounts for half of the world's total, reaching 466,000 and 422,000, respectively, and has placed a huge burden of disease on society, patients and their families, which need to be overcome urgentlyAs most liver cancer patients suffer from hepatitis, cirrhosis, abnormal liver function and other liver disease, when the disease is hidden, rapid progress, diagnosis is up to the middle and late stage, loss of surgery and other local treatment of the best time, treatment difficult, poor prognosis, resulting in the number of deaths and incidenceins in the world or China are in the forefrontthe development of liver cancer treatment is full of challengesPrior to 2007, liver cancer, which recurs after advanced liver cancer or surgery and ablation therapy, could only be treated with the disease, with a median natural survival of only about 100 daysProfessor Bi Feng of Huaxi Hospital, Sichuan University, one of the lead authors of the ZGDH3 study, said that in the past decade, the breakthrough in liver cancer research has been very limited, even today we are very hot tumor immunotherapy in the field of liver cancer is not very effectiveChina is a big liver cancer country, China's liver cancer and European and American cases have a high degree of heterogeneity, can not copy the experience of clinical treatment abroad, for the development of new drugs, exploration is increasingly urgent, Donovan is born in such thinkingas a large-scale registered clinical study developed by China and led by Chinese scholars to treat advanced hepatocellular carcinoma, ZGDH3 stood out from the more than 6,300 contributions of the ASCO Academic Conference and was listed as an oral report of the General Assembly, which represents the high recognition of the international academic community One of the lead authors of the ZGDH3 study, Professor Qin Shuxuan of Nanjing Jinling Hospital, said that after the advent of Sorafeni in 2007, molecular targeting has made some progress in the treatment of liver cancer, but despite this, the effect of liver cancer treatment is not satisfactory As a result, all researchers and pharmaceutical companies are working hard to get more and better molecular targeting drugs to market after Sorafini Unfortunately, in all the first-line studies of advanced liver cancer, the head-to-head comparison with Sorafini has failed in succession The domestic innovation drug Donafini achieved the excellent results with a smaller therapeutic dose in the trial with Sorafenib head-to-head, which is a major breakthrough in the field of liver cancer, and also laid a good foundation for the future combination treatment of liver cancer ZGDH3 is the first clinical trial in China to evaluate phase II/III of the first-line treatment of advanced hepatocellular carcinoma in China, with a total of 668 Chinese patients, making it the largest clinical trial of first-line advanced liver cancer in China to date The results showed that the main end-point total lifetime (OS) Donafini group was better than the control Sorafeni group, which reached 12.1 months in the Donafini group, while the Sorafini group was 10.3 months, a difference of 1.8 months In terms of safety, the adverse reaction spectrum was similar in both groups, and the Donafini group showed an overall safety trend that was better than the Sorafeni group "The core values of Zeai Pharmaceuticals are the development and production of high-quality, safe and effective, patient-free new drugs, committed to the development of human health," said Dr Sheng Zelin, Chairman of Zeyi Pharmaceuticals As the first heavy-duty drug of Zee-jin Pharmaceuticals, Donatini has received a number of "national major new drug creation special" support, based on the results of the asCO published trial, we also submitted a new drug market application, hoping that China's liver cancer patients can benefit from China's medical development as soon as possible In the future, Zeyu will continue to develop, and strive to market a new product every year, in clinical II, PHASE III products, the fastest speed to market, to give patients the greatest help "
with the joint efforts of Chinese innovative pharmaceutical companies and clinical researchers, the success of the experiment of Donovan indicates that domestic pharmaceutical innovation is no longer in the international stage of catching up with liver cancer, but is the first to achieve a breakthrough I believe that in the future, Donovan will definitely go abroad, not only for China's liver cancer patients, but also for liver cancer patients around the world to bring survival benefits